Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cancer Risk Following HLA-Incompatible Living Donor Kidney Transplantation.
Transplant Direct
August 2023
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Unlabelled: Incompatible living donor kidney transplant recipients (ILDKTr) require desensitization to facilitate transplantation, and this substantial upfront immunosuppression may result in serious complications, including cancer.
Methods: To characterize cancer risk in ILDKTr, we evaluated 858 ILDKTr and 12 239 compatible living donor kidney transplant recipients (CLDKTr) from a multicenter cohort with linkage to the US transplant registry and 33 cancer registries (1997-2016). Cancer incidence was compared using weighted Cox regression.
The real unmet need: A multifactorial approach for identifying sensitized kidney candidates with low access to transplant.
Clin Transplant
May 2023
United Network for Organ Sharing, Richmond, Virginia, USA.
Background: At the start of 2020, the kidney waiting list consisted of 2526 candidates with a calculated panel reactive antibody (CPRA) of 99.9% or greater, a cohort demonstrated in published research to have meaningfully lower than average access to transplantation even under the revised kidney allocation system (KAS).
Methods: This was a retrospective analysis of US kidney registrations using data from the OPTN [Reference (https://optn.
Analysis of de novo donor-specific HLA-DPB1 antibodies in kidney transplantation.
HLA
November 2021
Transplantation Immunology, Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany.
HLA matching and avoidance of unacceptable mismatches are important aspects in the selection of donors for solid organ transplantation. The impact of HLA-DPB1 incompatibility on the outcomes of kidney transplantation is not fully understood. We investigated a potential effect of mismatching for HLA-DPB1 at allele, eplet, or Terasaki epitope (TerEp) level on the formation of de novo donor-specific antibodies (dnDSA) and also asked whether polymorphisms associated with HLA-DPB1 expression level may influence dnDSA induction.
View Article and Find Full Text PDFIMPACT OF HLA-DPB1 MATCHING ON CLINICAL OUTCOMES AFTER HAPLOIDENTICAL-RELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION.
Rev Invest Clin
April 2021
Department of Hematology, Internal Medicine Division, Hospital Universitario "Dr. José E. González", School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico.
Background: The impact of HLA-DPB1 compatibility and its role as a transplantation antigen in haploidentical-related hematopoietic stem cell transplant (haplo-R-HSCT) have not been established, and a negative effect on survival has been suggested.
Objective: The objective of the determine was to study the frequency and clinical effects of incompatibility at the HLA-DPB1 locus in the haplo-R-HSCT setting.
Methods: Clinical records and electronic files of 91 patients with a hematological disease who underwent haplo-HSCT from January 2009 to October 2017 in a university medical center were scrutinized.
Impact of HLA-DPB1 Matching on Outcome of Unrelated Transplant for Hematologic Malignant Diseases: A Systematic Review and Meta-analysis.
Transplant Proc
November 2019
Department of Neurology, the First Affliated Hospital (School of Clinical Medicine) of Nanchang University, Nanchang, Jiangxi, China. Electronic address:
Objective: Human leukocyte antigen match is the most important donor factor affecting transplant outcome. The HLA-DPB1 mismatch on the clinical outcome of hematopoietic stem cell transplant (HSCT) is less clear. This study is the first meta-analysis to investigate the impact of HLA-DPB1 loci mismatch on clinical outcome after unrelated donor HSCT for hematologic malignant disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!